News & Publications

News & Publications

HighField Press Releases

HighField Biopharmaceuticals Presents Clinical Trial Sample Analysis of 2 Novel Lipid-Based Immuno-Oncology Therapeutics at the Society for Immunotherapy of Cancer (SITC) 2025 Meeting

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

HighField Biopharmaceuticals’ Clearance for Phase 2 Trial of HF1K16, a Unique Myeloid Cell Directed Immune Modulator, Follows Phase 1 Results to be Presented at AACR 2025 Meeting

Studies by HighField Biopharmaceuticals Show Advantages of Lipid Structure Design for Applying LNP Non-Viral Gene Therapies to Complex Diseases

HighField in the News

BioSpace: Data from a Phase 1 Trial of HighField Biopharmaceuticals’ HF1K16 Show the New Immuno-Oncology Drug is Safe and Signals Efficacy in Treating Refractory Metastatic Cancers

Clinical Trials Arena: HighField Bio initiates its glioma trial with first patient dosing

Biospace: HighField Biopharmaceuticals Announces First Patient Dosed in Phase 1b/2 Trial of HF1K16 for Recurrent and Refractory Glioma

Biospace: HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Publications

SITC 2025 Poster: Targeting MDSCs with HF1K16 Unlocks Long-Term Survival in Refractory Recurrent Glioma: an update of NCT05388487

SITC 2025 Poster: First-in-Human Evaluation of HF50, a Novel Liposomal HER2xCD3 T Cell Engager with TLR Agonist Payload, Demontrates Tolerability and Early Clinical Response

ASCO Breakthrough 2024 Poster: Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma

American Diabetes Association 2024 Poster: Preliminary study of efficacy and duration of an mRNA based GLP-1R agonist in diabetic monkeys

Liposomes : Methods and Protocols: Preparation and Characterization of Trastuzumab Fab-Conjugated Liposomes (Immunoliposomes)

Scientific References

Sustained Drug Release From Liposomes for the Remodeling of Systemic Immune Homeostasis and the Tumor Microenvironment

Comparative properties and methods of preparation of lipid vesicles (liposomes)

Gluagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection

Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma

Liposomal T cell engager and re-director for tumor cell eradication in cancer immunotherapy

Upcoming HighField Events

The current query has no posts. Please make sure you have published items matching your query.